Rapidly proliferating cells

Rapidly proliferating cells are characterized by their high rate of division and frequent progression through the cell cycle phases (G1, S, G2, and M). In the context of oncology, these cells are the primary focus of broad-spectrum chemotherapy, which utilizes cytotoxic agents to disrupt DNA integrity or the mitotic apparatus [1]. Because these drugs target the process of division itself rather than a unique oncogenic protein, they also impact healthy tissues with high turnover rates, such as the hematopoietic system, intestinal epithelium, and hair follicles [2]. This lack of selectivity results in systemic toxicities like neutropenia, mucositis, and alopecia. Consequently, while the term refers to the physiological target of traditional chemotherapy, it does not represent a single molecular target but rather a cellular state or phenotype [3].

Other names

Mitotically active cellsCycling cellsHyperproliferative cellsDividing cells

Broad-spectrum chemotherapeutic agents target rapidly proliferating cells by inducing DNA damage (alkylating agents), inhibiting DNA synthesis (antimetabolites), or interfering with microtubule dynamics (taxanes and vinca alkaloids), ultimately triggering apoptosis during the cell cycle [1][2].